Opinion

Video

Overview of Clinical Trials for New Imaging Options for Kidney Cancer

Author(s):

Neal Shore, MD, FACS,Brian M. Shuch, MD

Urologists review clinical trials investigating new imaging options in kidney cancer, including the ZIRCON study looking at girentuximab.

Related Videos
Chad Tang, MD: Considerations for SBRT in metastatic RCC
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
Human kidney cross section on scientific background | © Crystal light - stock.adobe.com
Jaleh Fallah, MD, answers a question during a Zoom video interview
Human kidney cross section on science background | Image Credit: © Rasi - stock.adobe.com
Human kidney cross section on science background | Image Credit: © Crystal light - stock.adobe.com
Related Content
First patient dosed in phase 1 trial of ADI-270 in ccRCC
December 19th 2024

First patient dosed in phase 1 trial of ADI-270 in ccRCC

Hannah Clarke
Initial data from the trial are expected to be released in the first half of 2025.
Belzutifan nears EU approval for advanced renal cell carcinoma
December 13th 2024

Belzutifan nears EU approval for advanced renal cell carcinoma

Hannah Clarke
A final decision on marketing authorization is anticipated for Q1 of 2025.
Phase 1/2 trial launches of CAR T cell therapy for ccRCC
November 20th 2024

Phase 1/2 trial launches of CAR T cell therapy for ccRCC

Hannah Clarke
Initial results on ADI-270 are anticipated for the first half of 2025.
ALLO-316 shows encouraging CAR activity in advanced ccRCC
November 8th 2024

ALLO-316 shows encouraging CAR activity in advanced ccRCC

Hannah Clarke
Overall, 76% of patients with a CD70 TPS of at least 50% achieved a reduction in tumor burden.
Casdatifan demonstrates encouraging clinical activity in renal cell carcinoma
November 4th 2024

Casdatifan demonstrates encouraging clinical activity in renal cell carcinoma

Hannah Clarke
“Based on these data, casdatifan has the potential to be a future treatment option for kidney cancer," says Toni K. Choueiri, MD.
FDA grants Regenerative Medicine Advanced Therapy designation to ALLO-316 for RCC
October 29th 2024

FDA grants Regenerative Medicine Advanced Therapy designation to ALLO-316 for RCC

Hannah Clarke Gina Mauro
The RMAT designation is supported by interim data from the ongoing phase 1 TRAVERSE trial.
© 2024 MJH Life Sciences

All rights reserved.